Research and experimental development on natural sciences and engineering
PROPHYLAXIA SIGNS AS
Revenue 2024
NOK 3.9m
Operating profit
NOK 922,000
Equity
NOK −3.1m
Incorporated
2010
Share capital
NOK 150,000
Key figures · 2024
Current ratio
1.28
Equity ratio
-127.9%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | 23.9% | |
| Net margin (%%) | 14.0% | |
| Return on assets (%%) | 37.5% | |
| Likviditet | ||
| Current ratio | 1.28 | |
| Working capital | 537k | |
| Soliditet | ||
| Equity ratio (%%) | -127.9% | |
| Debt-to-equity ratio | -1.78 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.